{"disease":{"id":"impaired-renal-function","name":"impaired renal function"},"drugs":{"marketed":[{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with impaired renal function.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01716455","title":"Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT06761131","title":"Compare Linezolid-Induced Thrombocytopenia in Patients With Normal Renal Function Versus Impaired Renal Function","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT04179630","title":"Study of Aldafermin (NGM282) in Participants With Impaired Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"NGM Biopharmaceuticals, Inc","has_results":false},{"nct_id":"NCT02431481","title":"Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02965040","title":"A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":false},{"nct_id":"NCT02603497","title":"Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT03776539","title":"A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Eloxx Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04414852","title":"A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04252430","title":"RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"MedDay Pharmaceuticals SA","has_results":false},{"nct_id":"NCT04699877","title":"A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT04620590","title":"Dapagliflozin Treatment in Type 2 Diabetes","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Emerald Clinical Inc.","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}